Response of Human Epidermal Growth Factor Receptor 2-Expressing Prostate Cancer to Trastuzumab Deruxtecan.

Autor: Lap CJ; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Rajendran R; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Martin JM; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Uppal M; The George Washington University School of Medicine, Washington, DC., Escobar A; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Heiraty AM; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Estephan F; The George Washington University School of Medicine, Washington, DC., Hahn W; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Subrahmanyam R; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Nava VE; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and The George Washington University School of Medicine, Washington, DC., Jain M; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and The George Washington University School of Medicine, Washington, DC.

Publikováno v: Annals of internal medicine [Ann Intern Med] 2024 Dec; Vol. 177 (12), pp. 1738-1741. Date of Electronic Publication: 2024 Nov 05.

The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.

Autor: Estephan F; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Lap CJ; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Banagan J; Institute for Clinical Research, Washington, DC, USA., Antonio M; Institute for Clinical Research, Washington, DC, USA., Liu S; Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, Washington, DC, USA., Diao G; Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, Washington, DC, USA., Rozalen AZ; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Rajendran R; Institute for Clinical Research, Washington, DC, USA., Krasnow S; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Subrahmanyam R; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Nava VE; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Jain M; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA. Electronic address: maneesh.jain@va.gov.

Publikováno v: Annals of diagnostic pathology [Ann Diagn Pathol] 2023 Dec; Vol. 67, pp. 152219. Date of Electronic Publication: 2023 Oct 20.

Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics.

Autor: Mavingire, Nicole¹ (AUTHOR) nmavingire@msm.edu, Moore, Janelle C.¹ (AUTHOR) jcmoore@msm.edu, Johnson, Jabril R.² (AUTHOR) jabjohnson@msm.edu, Dwead, Abdulrahman M.¹ (AUTHOR), Cropp, Cheryl D.³ (AUTHOR) ccropp@msm.edu, Mechref, Yehia⁴ (AUTHOR), Kobeissy, Firas⁵ (AUTHOR) fkobaissy@msm.edu, Rais-Bahrami, Soroush^6,7,8 (AUTHOR) sraisbahrami@uabmc.edu, Woods-Burnham, Leanne¹ (AUTHOR) lburnham@msm.edu

Publikováno v: Cancers. Oct2024, Vol. 16 Issue 19, p3262. 19p.

White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.

Autor: Estephan F; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Ye X; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Dzaye O; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Radiology and Neuroradiology, Charité, Berlin, Germany., Wagner-Johnston N; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Swinnen L; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Gladstone DE; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Ambinder R; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Kamson DO; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Lambrecht S; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Grossman SA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Lin DDM; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ddmlin@jhmi.edu.; Division of Neuroradiology, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA. ddmlin@jhmi.edu., Holdhoff M; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. mholdho1@jhmi.edu.; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Viragh Building, 9th floor, 201 North Broadway, Mailbox 3, Baltimore, MD, 21287, USA. mholdho1@jhmi.edu.

Publikováno v: Journal of neuro-oncology [J Neurooncol] 2019 Dec; Vol. 145 (3), pp. 461-466. Date of Electronic Publication: 2019 Oct 16.

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.

Autor: Phelan JD; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Young RM; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Webster DE; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Roulland S; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Aix-Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France., Wright GW; Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kasbekar M; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Shaffer AL 3rd; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ceribelli M; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Gaithersburg, MD, USA., Wang JQ; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Schmitz R; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Nakagawa M; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Bachy E; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Huang DW; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ji Y; Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany., Chen L; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Gaithersburg, MD, USA., Yang Y; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zhao H; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yu X; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Xu W; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Palisoc MM; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Valadez RR; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Davies-Hill T; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wilson WH; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Chan WC; Departments of Pathology, City of Hope National Medical Center, Duarte, CA, USA., Jaffe ES; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gascoyne RD; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Campo E; Hospital Clinic, University of Barcelona, Barcelona, Spain., Rosenwald A; Institute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Ott G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany., Delabie J; University Health Network, Laboratory Medicine Program, Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada., Rimsza LM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA., Rodriguez FJ; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Estephan F; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Holdhoff M; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Kruhlak MJ; Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hewitt SM; Experimental Pathology Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Thomas CJ; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Gaithersburg, MD, USA., Pittaluga S; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Oellerich T; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. thomas.oellerich@kgu.de.; Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany. thomas.oellerich@kgu.de.; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany. thomas.oellerich@kgu.de., Staudt LM; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. lstaudt@mail.nih.gov.

Publikováno v: Nature [Nature] 2018 Aug; Vol. 560 (7718), pp. 387-391. Date of Electronic Publication: 2018 Jun 20.